Denali Therapeutics Overview
Valuation check: DNLI's ROE is -61.24%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow-61.24%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Denali Therapeutics (DNLI) currently reports a ROE of -61.24%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Denali Therapeutics's ROE history and peer comparisons.
Denali Therapeutics's ROE of -61.24% is lower than the Healthcare sector average of 20.86%. That is roughly 393.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Denali Therapeutics's current -61.24% should be judged against Healthcare norms (sector average: 20.86%) and against DNLI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -61.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Denali Therapeutics, and consider following DNLI for alerts when major investors trade the stock.
Denali Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -61.24% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNLI with unrelated industries.
